With global expansion planned, Krystal lays out blockbuster ambitions for topical gene therapy
Fierce Pharma
FEBRUARY 26, 2024
Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. | In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million.
Let's personalize your content